November 12, 2019 06:55 AM EST
R&D

Safe­ty qualms in MyoKar­dia mid-stage study cause in­vestors to pause

Natalie Grover

Reporter

Ahead of the piv­otal da­ta read­out of MyoKar­dia’s lead drug, mava­camten, in pa­tients with ob­struc­tive hy­per­trophic car­diomy­opa­thy (HCM), in­vestors took is­sue with the drug’s safe­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times